Description
N-terminal His6-tagged recombinant, human Abl, amino acids 27-end containing the M351T mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the M351T mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125)